Marie Jaspard1, Mamadou Saliou Sow2, Sylvain Juchet3, Eric Dienderé4, Beatrice Serra5, Richard Kojan6, Billy Sivahera7, Caroline Martin8, Moumouni Kinda9, Hans-Joerg Lang10, Fodé Bangaly Sako11, Fodé Amara Traoré12, Eudoxie Koumbem13, Halidou Tinto14, Adama Sanou15, Apoline Sondo16, Flavien Kaboré17, Joseph Donamou18, Jean-Paul-Yassa Guilavogui19, Fanny Velardo20, Brice Bicaba21, Olivier Marcy22, Augustin Augier23, Sani Sayadi24, Armel Poda25, Sakoba Keita26, Xavier Anglaret27, Denis Malvy28. 1. The Alliance for International Medical Action (ALIMA), Dakar, Senegal; Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France. Electronic address: marie.jaspard@coral.alima.ngo. 2. Service des maladies infectieuses, Hôpital National Donka, Conakry, Guinée. Electronic address: smsaliou@gmail.com. 3. The Alliance for International Medical Action (ALIMA), Dakar, Senegal; Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France. Electronic address: sylvain.juchet@coral.alima.ngo. 4. Service de Médecine interne - Maladies infectieuses, CHU de Bogodogo, Ouagadougou, Burkina Faso. Electronic address: ericarno@hotmail.fr. 5. The Alliance for International Medical Action (ALIMA), Dakar, Senegal; Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France. Electronic address: beatrice.serra@coral.alima.ngo. 6. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: richard.kojan@alima.ngo. 7. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: billy.sivahera@alima.ngo. 8. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: covid.arccoverage@guinee.alima.ngo. 9. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: Moumouni.kinda@alima.ngo. 10. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: hansjoerg.lang@alima.ngo. 11. Service des maladies infectieuses, Hôpital National Donka, Conakry, Guinée. Electronic address: sakofb@yahoo.fr. 12. Service des maladies infectieuses, Hôpital National Donka, Conakry, Guinée. Electronic address: fatraore01@gmail.com. 13. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: eudoxie.koumbem@gmail.com. 14. Clinical Research Unit of Nanoro, National Center for Scientific and Technological Research, Ouagadougou, Burkina Faso. Electronic address: halidoutinto@gmail.com. 15. Direction des services médicaux et médicotechniques du Centre Hospitalier Universitaire de Tengandogo, Ouagadougou, Burkina Faso. Electronic address: sanoua14@yahoo.fr. 16. Service des Maladies infectieuses et tropicales. Centre Hospitalier Universitaire de Yalgado Ouedraogo, Ouagadougou, Burkina Faso. Electronic address: sondoapoline@yahoo.fr. 17. Service d'anesthésie réanimation, Centre Hospitalier Universitaire de Tengandogo, Ouagadougou, Burkina Faso. Electronic address: kflavien72@yahoo.fr. 18. Service d'anesthésie et de réanimation, Hôpital National Donka, Conakry, Guinée. Electronic address: donamoujoseph@yahoo.fr. 19. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: guilavoguijp@gmail.com. 20. Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France. Electronic address: fanny.velardo@u-bordeaux.fr. 21. Centre des Opérations et Réponses aux Urgences sanitaires du Burkina Faso. Electronic address: bicaba_brico@yahoo.fr. 22. Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France. Electronic address: olivier.marcy@u-bordeaux.fr. 23. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: aug@alima.ngo. 24. The Alliance for International Medical Action (ALIMA), Dakar, Senegal. Electronic address: guinee.cdm@alima.ngo. 25. Institut National des Sciences de la Santé (INSSA), Université Nazi Boni, Bobo-Dioulasso, Burkina Faso. Electronic address: armelpoda@yahoo.fr. 26. Agence Nationale de Sécurité Sanitaire (ANSS), Conakry, Guinée. Electronic address: keita_sakoba@yahoo.fr. 27. The Alliance for International Medical Action (ALIMA), Dakar, Senegal; Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France. Electronic address: xavier.anglaret@u-bordeaux.fr. 28. Inserm 1219, Univ. Bordeaux, IRD, Bordeaux, France; Department of Infectious Diseases and Tropical Medicine, CHU de Bordeaux, Hôpital Pellegrin, Bordeaux, France. Electronic address: denis.malvy@chu-bordeaux.fr.
Abstract
OBJECTIVES: In Africa, the overall death toll from COVID-19 is reported to be low but there is few individual-level evidence on the severity of the disease. We report the clinical spectrum and outcome of patients monitored in COVID-19 care centers (CCC) in two West-African countries. METHODS: Burkina Faso and Guinea set up referral CCCs to hospitalize all symptomatic SARS-CoV-2 carriers, regardless of the severity of their symptoms. We report the data collected from hospitalized patients by November 2020. RESULT: 1805 patients (64% men, median age 41) were admitted with COVID-19. Symptoms lasted for a median of 7 days (IQR 4-11). During hospitalization, 443 (25%) had at least once a SpO2 < 94%, 237 (13%) received oxygen and 266 (15%) corticosteroids. Mortality was 5% overall, and 1%, 5% and 14% in patients aged <40, 40-59 and ≥60. In multivariable analysis, the risk of death was higher in men (aOR 2.0, 95%CI 1.1;3.6), people aged ≥60 (aOR 2.9, 95%CI 1.7;4.8) and those with chronic hypertension (aOR 2.1, 95%CI 1.2;3.4). CONCLUSION: COVID-19 is as severe in Africa as elsewhere and common risk factors such as greater age and hypertension should make us vigilant.
OBJECTIVES: In Africa, the overall death toll from COVID-19 is reported to be low but there is few individual-level evidence on the severity of the disease. We report the clinical spectrum and outcome of patients monitored in COVID-19 care centers (CCC) in two West-African countries. METHODS: Burkina Faso and Guinea set up referral CCCs to hospitalize all symptomatic SARS-CoV-2 carriers, regardless of the severity of their symptoms. We report the data collected from hospitalized patients by November 2020. RESULT: 1805 patients (64% men, median age 41) were admitted with COVID-19. Symptoms lasted for a median of 7 days (IQR 4-11). During hospitalization, 443 (25%) had at least once a SpO2 < 94%, 237 (13%) received oxygen and 266 (15%) corticosteroids. Mortality was 5% overall, and 1%, 5% and 14% in patients aged <40, 40-59 and ≥60. In multivariable analysis, the risk of death was higher in men (aOR 2.0, 95%CI 1.1;3.6), people aged ≥60 (aOR 2.9, 95%CI 1.7;4.8) and those with chronic hypertension (aOR 2.1, 95%CI 1.2;3.4). CONCLUSION:COVID-19 is as severe in Africa as elsewhere and common risk factors such as greater age and hypertension should make us vigilant.
Authors: Lily D Yan; Sarah S Matuja; Kevin J Pain; Margaret L McNairy; Anthony O Etyang; Robert N Peck Journal: Hypertension Date: 2022-03-11 Impact factor: 9.897
Authors: Kayode Oshinubi; Sana S Buhamra; Noriah M Al-Kandari; Jules Waku; Mustapha Rachdi; Jacques Demongeot Journal: Healthcare (Basel) Date: 2022-03-04